| 1 |
Phase 2a (therapeutic exploratory) trial of SB17170 in patients with idiopathic pulmonary fibrosis |
| Small molecules |
IPF |
HMGB1 |
Phase 2 |
|
RS-2026-25502804 |
|
| 2 |
Development of Novel Agents for Idiopathic Pulmonary Fibrosis: Phase 2a Clinical Trial and phase 2b approval of BBT-877, autotaxin inhibitor, in IPF patients |
| Small molecules |
Idiopathic pulmonary fibrosis |
Autotacxin |
Phase 2 |
Bridge Biotherapeutics, Inc. |
RS-2023-00219938 |
|
| 3 |
Clinical Trial Development of A Novel Small Molecule Inhibitor for Idiopathic Pulmonary Fibrosis Treatment |
| Small molecules |
IPF |
Prolyl-tRNA synthetase (PRS) |
Phase 2 |
Daewoong Pharmaceutical Co., Ltd. |
RS-2022-00166689 |
|